Oroxin B Resembles Bisoprolol in Attenuating Beta1-Adrenergic Receptor Autoantibody-Induced Atrial Remodelling via the PTEN/AKT/mTOR Signalling Pathway

IF 2.9 4区 医学 Q2 Medicine
Na Yang, Huaxin Sun, Linqiang Xi, Ling Zhang, Yanmei Lu, Qianhui Wang, Jiaru Cao, Jie Song, Baopeng Tang, Luxiang Shang, Xianhui Zhou
{"title":"Oroxin B Resembles Bisoprolol in Attenuating Beta1-Adrenergic Receptor Autoantibody-Induced Atrial Remodelling via the PTEN/AKT/mTOR Signalling Pathway","authors":"Na Yang,&nbsp;Huaxin Sun,&nbsp;Linqiang Xi,&nbsp;Ling Zhang,&nbsp;Yanmei Lu,&nbsp;Qianhui Wang,&nbsp;Jiaru Cao,&nbsp;Jie Song,&nbsp;Baopeng Tang,&nbsp;Luxiang Shang,&nbsp;Xianhui Zhou","doi":"10.1111/1440-1681.70011","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Beta1-adrenergic receptor autoantibodies (β1-AAbs) promote atrial remodelling and ultimately lead to the development of atrial fibrillation (AF). Oroxin B is a natural flavonoid glycoside with a variety of biological activities, including anti-inflammatory and autophagy-promoting effects, and has therapeutic benefits for a variety of diseases. The aim of this study was to investigate the potential therapeutic role of Oroxin B in the development of β1-AAb-induced atrial fibrillation and to elucidate the underlying mechanisms involved. We established a rat model of β1-AAb-induced atrial fibrillation via active immunisation. The first stage was divided into three groups: the control group, the β1-AAb group and the β1-AAb + bisoprolol group. The second stage was divided into three groups: the control group, the β1-AAb group and the β1-AAb + Oroxin B group. Serum levels of β1-AAbs, atrial tissue levels of cyclic monophosphate (cAMP), atrial electrophysiological parameters, cardiac structure and function, mitochondrial structure, autophagy levels, cardiomyocyte apoptosis and myocardial fibrosis were examined. The results showed that bisoprolol, a β1-blocker, improved β1-AAb-induced atrial electrical remodelling, reduced atrial collagen deposition, ameliorated the increase in LAD and regulated the balance of autophagy and apoptosis in atrial myocytes through the PTEN/AKT/mTOR signalling pathway. Oroxin B, a PTEN agonist, can improve the impairment of autophagy homeostasis and apoptosis in atrial tissue by activating the PTEN/AKT/mTOR signalling pathway, thereby improving atrial structure and electrical remodelling. Moreover, Oroxin B may play a therapeutic role in β1AAb-induced atrial fibrillation. In conclusion, our results demonstrate the potential therapeutic role of Oroxin B in β1AAb-induced atrial fibrillation and the underlying mechanisms, suggesting that Oroxin B may be an effective antiarrhythmic medication.</p>\n </div>","PeriodicalId":50684,"journal":{"name":"Clinical and Experimental Pharmacology and Physiology","volume":"52 2","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Pharmacology and Physiology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1440-1681.70011","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Beta1-adrenergic receptor autoantibodies (β1-AAbs) promote atrial remodelling and ultimately lead to the development of atrial fibrillation (AF). Oroxin B is a natural flavonoid glycoside with a variety of biological activities, including anti-inflammatory and autophagy-promoting effects, and has therapeutic benefits for a variety of diseases. The aim of this study was to investigate the potential therapeutic role of Oroxin B in the development of β1-AAb-induced atrial fibrillation and to elucidate the underlying mechanisms involved. We established a rat model of β1-AAb-induced atrial fibrillation via active immunisation. The first stage was divided into three groups: the control group, the β1-AAb group and the β1-AAb + bisoprolol group. The second stage was divided into three groups: the control group, the β1-AAb group and the β1-AAb + Oroxin B group. Serum levels of β1-AAbs, atrial tissue levels of cyclic monophosphate (cAMP), atrial electrophysiological parameters, cardiac structure and function, mitochondrial structure, autophagy levels, cardiomyocyte apoptosis and myocardial fibrosis were examined. The results showed that bisoprolol, a β1-blocker, improved β1-AAb-induced atrial electrical remodelling, reduced atrial collagen deposition, ameliorated the increase in LAD and regulated the balance of autophagy and apoptosis in atrial myocytes through the PTEN/AKT/mTOR signalling pathway. Oroxin B, a PTEN agonist, can improve the impairment of autophagy homeostasis and apoptosis in atrial tissue by activating the PTEN/AKT/mTOR signalling pathway, thereby improving atrial structure and electrical remodelling. Moreover, Oroxin B may play a therapeutic role in β1AAb-induced atrial fibrillation. In conclusion, our results demonstrate the potential therapeutic role of Oroxin B in β1AAb-induced atrial fibrillation and the underlying mechanisms, suggesting that Oroxin B may be an effective antiarrhythmic medication.

Abstract Image

Oroxin B与比索洛尔相似,通过PTEN/AKT/mTOR信号通路减弱β -肾上腺素能受体自身抗体诱导的心房重构
β -肾上腺素能受体自身抗体(β1-AAbs)促进心房重构,最终导致心房颤动(AF)的发生。Oroxin B是一种天然类黄酮苷,具有多种生物活性,包括抗炎和促进自噬作用,对多种疾病有治疗作用。本研究的目的是探讨Oroxin B在β1- aab诱发的房颤发展中的潜在治疗作用,并阐明其潜在机制。通过主动免疫建立大鼠β1- aab心房颤动模型。第一阶段分为3组:对照组、β1-AAb组和β1-AAb +比索洛尔组。第二阶段分为3组:对照组、β1-AAb组和β1-AAb + Oroxin B组。检测血清β1-自身抗体水平、心房组织环磷酸腺苷(cAMP)水平、心房电生理参数、心脏结构和功能、线粒体结构、自噬水平、心肌细胞凋亡和心肌纤维化。结果表明,β1阻断剂比索洛尔通过PTEN/AKT/mTOR信号通路改善β1- aab诱导的心房电重构,减少心房胶原沉积,改善LAD升高,调节心房肌细胞自噬和凋亡平衡。Oroxin B是一种PTEN激动剂,可通过激活PTEN/AKT/mTOR信号通路,改善心房组织自噬稳态受损和凋亡,从而改善心房结构和电重构。此外,Oroxin B可能在β 1ab诱发的心房颤动中发挥治疗作用。总之,我们的研究结果证明了Oroxin B在β 1ab诱导的心房颤动中的潜在治疗作用及其机制,表明Oroxin B可能是一种有效的抗心律失常药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
128
审稿时长
6 months
期刊介绍: Clinical and Experimental Pharmacology and Physiology is an international journal founded in 1974 by Mike Rand, Austin Doyle, John Coghlan and Paul Korner. Our focus is new frontiers in physiology and pharmacology, emphasizing the translation of basic research to clinical practice. We publish original articles, invited reviews and our exciting, cutting-edge Frontiers-in-Research series’.
文献相关原料
公司名称
产品信息
索莱宝
BCA protein assay kit
索莱宝
RIPA lysis buffer
索莱宝
BCA protein assay kit
索莱宝
RIPA lysis buffer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信